FGF21 improves the metabolic profile of obese animals through its actions on adipocytes. To elucidate the signaling network responsible for mediating these effects, we quantified dynamic changes in the adipocyte phosphoproteome following acute exposure to FGF21. FGF21 regulated a network of 821 phosphosites on 542 proteins. A major FGF21-regulated signaling node was mTORC1/S6K. In contrast to insulin, FGF21 activated mTORC1 via MAPK rather than through the canonical PI3K/AKT pathway. Activation of mTORC1/S6K by FGF21 was surprising because this is thought to contribute to deleterious metabolic effects such as obesity and insulin resistance. Rather, mTORC1 mediated many of the beneficial actions of FGF21 in vitro, including UCP1 and FGF21 induction, increased adiponectin secretion, and enhanced glucose uptake without any adverse effects on insulin action. This study provides a global view of FGF21 signaling and suggests that mTORC1 may act to facilitate FGF21-mediated health benefits in vivo.
INTRODUCTION
Fibroblast growth factor 21 (FGF21) extends lifespan and exerts numerous health benefits, including improved insulin sensitivity and reduced adiposity and hepatic steatosis (Kharitonenkov et al., 2005 (Kharitonenkov et al., , 2007 Zhang et al., 2012) . FGF21 mediates its effects by stimulating fibroblast growth factor receptor (FGFR) 1/2 in complex with the coreceptor b-klotho (Ogawa et al., 2007) . Knockout of FGFR1 or b-klotho in adipocytes, or knockout of b-klotho in CNS, prevents FGF21-mediated improvements in insulin sensitivity and reductions in adiposity (Adams et al., 2012; Bookout et al., 2013; Ding et al., 2012; Owen et al., 2014) , while inhibition of b-klotho in the liver prevents FGF21-mediated reduction in hepatic steatosis (Gong et al., 2016) . Antibodymediated activation of FGFR1c-b-klotho, which activates FGF21 signaling in adipocytes without detectable effects in liver or CNS, recapitulates the beneficial metabolic actions of FGF21 (Kolumam et al., 2015) . This suggests that FGF21 signaling in adipocytes is crucial for FGF21's actions. In adipocytes, FGF21 stimulates browning, adiponectin secretion, and glucose uptake (Fisher et al., 2012; Holland et al., 2013; Lin et al., 2013) , and these effects are thought to underpin the beneficial effects of FGF21.
Although much is known about FGF21 actions, there are major gaps in our understanding of the mechanisms underlying these effects. In particular, the intracellular signaling pathways that coordinate FGF21's effects are unclear. Given that protein phosphorylation networks process hormonal inputs into metabolic responses (Humphrey et al., 2015b) , we therefore sought to quantify the phosphoproteome of adipocytes acutely stimulated with FGF21 to provide a systems view of the signaling networks underlying the cellular response to this hormone.
RESULTS AND DISCUSSION

FGF21-Regulated Phosphorylation in Adipocytes
To map the FGF21 signaling network in adipocytes, 3T3-L1 adipocytes underwent stable isotope labeling by amino acids in cell culture (SILAC) (Ong et al., 2002) . Triple SILAC-labeled cells were stimulated with FGF21 to generate a time series spanning 30 s to 30 min (Olsen et al., 2006) . Phosphopeptides were enriched, and the phosphoproteome was analyzed by quantitative mass spectrometry (MS) in biological triplicates ( Figure 1A ). In total, we identified 15,687 phosphorylation sites on 4,583 distinct proteins, and 11,706 of these (median localization probability 0.994) were accurately localized to a single residue (Class 1 sites, localization probability R 0.75) ( Figure 1A) . A previous study quantified 1,186 phosphosites and identified 130 sites regulated by FGF21 (Muise et al., 2013) . Of the phosphorylation sites quantified across all time points (6,582 Class 1 sites) in our study, FGF21 significantly regulated 12.5% (821) by <0.67-fold or >1.5-fold (adjusted [adj.] p < 0.05) ( Figure 1A ), greatly expanding the known FGF21 signaling network in adipocytes. FGF21 signaling was initiated by tyrosine phosphorylation of FGFR1, closely followed by phosphorylation of ERK1 and 2 ( Figure 1B ). Following these events, the number of significantly FGF21-regulated phosphosites increased from just a few at 2 min to >550 after 5 min ( Figure 1C ).
We next searched for kinases that propagate FGF21 signaling downstream of ERK. In response to FGF21, 56 kinases were phosphorylated, 13 of which were phosphorylated on known activation sites. To identify activated kinases, we applied clustering and directional analysis to the temporal profiles of kinase substrates in our phosphoproteomics data Yang et al., 2014) . Kinases with enhanced activity in the FGF21-regulated phosphoproteome included ERK1/2, mTORC1, S6K, AKT, CHEK, PKA, and CDK2 ( Figure S1 ). 2015). Our phosphoproteomics data suggest that mTORC1 and S6K are key nodes in FGF21 signaling. The mTORC1 substrate and activation site of S6K1 (S444/ 427) was the third most highly phosphorylated kinase activation site (4.5-and 2.6-fold change at 5 min) after ERK2 T183/Y185 (13.7-and 8.0-fold change at 5 min) and FGFR1 Y653/Y654 (9.2-fold change at 2 min). In addition, at the peak of mTORC1 and S6K activity (5-30 min), FGF21 signaling activity became markedly amplified, and there was an enrichment of substrates containing mTOR, ERK, and S6K minimal consensus motifs ( Figures 1C-1E ). To confirm activation of mTORC1/S6K by FGF21 in vivo, we injected mice with FGF21 and removed adipose tissue at different times. Phosphorylation of ERK at its activation site (T183/Y185) was increased at 5 min, and mTORC1/S6K activity was elevated after 30 min, as assessed by phosphorylation of the S6K substrate 40S ribosomal protein S6 (RPS6) (S235/S236) ( Figure 1F ). Another study reported that chronic FGF21 administration (10 days) in mice inhibits mTORC1 activity in the liver (Gong et al., 2016) . This may therefore reflect the development of FGF21 resistance in the liver under these conditions or differential signaling in these cell types.
Intersection of FGF21 and Insulin Signaling Networks mTORC1 and S6K are also central to insulin signaling. However, as part of this network, they have been found to form part of a negative feedback loop that triggers insulin resistance and increased adiposity (Copps and White, 2012; Hsu et al., 2011; Um et al., 2004; Yu et al., 2011) . A comparison of the FGF21 and insulin phosphoproteomes (Humphrey et al., 2013) revealed that FGF21 signaling was in general slower than insulin but that 28% of FGF21-regulated phosphosites seen after 20 min of stimulation were also regulated by insulin after 20 min (Figure 2A) , suggesting a convergence of later signaling events. Using a kinase perturbation analysis (KinasePA, http://rp-www.cs.usyd. edu.au/yangpy/software/KinasePA.html) , we found that at these time points, insulin and FGF21 most strongly regulated the substrates of S6K, followed by ERK2, ERK1, RSK, and Akt ( Figure 2B ). However, Akt was more robustly activated by insulin, and when a manually curated subset of higher-confidence Akt substrates was used for this analysis, this difference was even greater ( Figure 2B ). These data suggest that in adipocytes, FGF21 and insulin share the mTORC1 and S6K network branches but may be differentiated by the robust early activation of Akt that occurs with insulin.
FGF21 Weakly Activates Akt but Robustly Activates MAPK
We next compared the effects of FGF21 on the Akt and mitogenactivated protein kinase (MAPK) pathways with a physiological dose of insulin (0.5 nM) (Winzell and Ahré n, 2004) . FGF21 had a transient and minor effect on Akt signaling compared to the physiological dose of insulin, whereas its stimulation of the MAPK pathway was 11-fold more potent than that observed with insulin ( Figure 2C ). Hence, this shows that the effects of FGF21 on MAPK are highly specific, and under physiological conditions, insulin may have a relatively minor effect on MAPK signaling in adipocytes.
Next, we examined whether the modest activation of Akt by FGF21 was biologically relevant. In contrast to insulin (10 nM), acute FGF21 treatment had no significant effect on glucose uptake or lipolysis ( Figures 2D and 2E ), two Akt-dependent processes (Tan et al., 2015) . In contrast, protein synthesis, which is largely an mTORC1-mediated process, was stimulated by both FGF21 and insulin, and this was blocked by the mTORC1 inhibitor rapamycin ( Figure 2F ). Collectively, these data indicate that FGF21 and insulin elicit distinct actions in adipocytes, partly because of differential signaling through Akt and MAPK.
FGF21 Activates mTORC1 via MAPK
The insulin receptor, like most tyrosine kinase receptors, activates mTORC1 through PI3K/Akt, whereas others, such as the epidermal growth factor (EGF) receptor, use the MAPK pathway (Carriere et al., 2011; Ma et al., 2005) . To determine whether FGF21-stimulated mTORC1 activity was MAPK or Akt dependent, we incubated cells with specific inhibitors of either Akt (MK-2206) or MEK (U0126), the kinase immediately upstream of ERK ( Figure 2G ). Only the MEK inhibitor prevented FGF21-mediated RPS6 and S6K phosphorylation, demonstrating that mTORC1 activation by FGF21 is dependent on MAPK, and not Akt, activity ( Figure 2G ).
FGF21-Induced mTORC1 Activation Does Not Lead to Insulin Resistance
It has been suggested that hyperinsulinemia induces insulin resistance via negative feedback pathways involving phosphorylation of insulin receptor substrate (IRS) proteins (Shah and Hunter, 2006; Shah et al., 2004; Um et al., 2004) . However, some studies have questioned the relevance of serine/threonine (Ser/Thr) IRS phosphorylation in mediating insulin resistance (Hoehn et al., 2008) . FGF21 stimulated IRS1 and IRS2 phosphorylation on sites previously implicated in insulin resistance, including S302, S307, and S522, on IRS1 ( Figure 3A ) (Shah and Hunter, 2006) . To determine whether this might induce insulin resistance, adipocytes were incubated with FGF21 (23 nM) for 16 hr. However, in contrast to chronic insulin treatment, which significantly impaired insulin-stimulated glucose uptake, chronic treatment with FGF21 had no significant impact on insulin action ( Figure 3B ). We also cotreated cells with FGF21 and insulin to investigate whether FGF21 could overcome the inhibitory effect of chronic insulin exposure. FGF21 did not improve insulin sensitivity in cells exposed to chronic insulin ( Figure 3B ). Rather FGF21 increased basal glucose uptake, likely due to increased GLUT1 expression (Palfreyman et al., 1992) . These findings indicate that FGF21-mediated Ser/Thr IRS phosphorylation does not cause insulin resistance in adipocytes.
mTORC1 Mediates FGF21-Induced Glucose Uptake, Adiponectin Secretion, and UCP1 Expression Next, we questioned whether mTORC1 may mediate the beneficial actions of FGF21. FGF21 is thought to induce weight loss and insulin sensitivity by stimulating glucose uptake, browning, and adiponectin secretion in adipocytes. To investigate whether these actions are mediated by mTORC1 and MAPK, we inhibited these kinases with rapamycin or U0126, respectively. Prolonged rapamycin treatment can also inhibit mTORC2. However, it is unlikely that this accounts for the effects of rapamycin on FGF21 action in adipocytes, because there was no significant increase in mTORC2 activity with FGF21, as demonstrated by measurement of Akt phosphorylation at the mTORC2 site S473 (Figure S2) . Thus, rapamycin treatment likely reflects a selective effect on mTORC1. Treatment of adipocytes with FGF21 for 16 hr increased glucose uptake by 3-fold, and this was blocked with either rapamycin or U0126 ( Figure 3C ). To assess browning and (B) 3T3-L1 adipocytes were treated with 10 nM insulin, 23 nM FGF21, or both for 16 hr, serum starved for 2 hr, and then assayed for glucose uptake without (basal) or with (10 nM) insulin for 30 min (n = 5, mean ± SEM, two-way ANOVA, *p < 0.01 versus insulin-stimulated control). Bottom: insulin-sensitive glucose uptake (D insulin-basal) is shown. Data are normalized to control (n = 5, mean ± SEM, one-sample t test, *p < 0.01).
(C-F) 3T3-L1 adipocytes (C) or subcutaneous adipocytes differentiated in vitro (D-F) were treated for 16 hr with 23 nM FGF21, 10 nM insulin, 500 nM rapamycin (R), or 10 mM U0126 (U). (C) Cells were serum starved and glucose uptake was assessed using
into cell culture media was detected by immunoblotting, and immunoblots were quantified and normalized to basal (n = 4). (E and F) FGF21 and UCP1 mRNAs were determined and normalized to basal (n = 8 for control and FGF21-treated cells, n = 5 for insulin-treated cells). Data presented are mean ± SEM. *p < 0.05 by two-way ANOVA versus FGF21-treated cells. #p < 0.01 one-way ANOVA versus untreated cells or for (D) one sample t test. NS, non-significant. adiponectin secretion, we used primary adipocytes, which were differentiated from a stromal vascular fraction (SVF) isolated from mouse subcutaneous adipose tissue. Primary adipocytes incubated with FGF21 for 16 hr increased adiponectin secretion by 40%, and this was inhibited by rapamycin ( Figure 3D ), while inhibition by U0126 was variable. Next we measured UCP1 mRNA levels as an index of adipocyte browning. Both rapamycin and U0126 inhibited FGF21-induced UCP1 expression (Figure 3E ). In the same cells, FGF21 also induced FGF21 gene expression, and this was rapamycin sensitive ( Figure 3F ). Incubation of adipocytes with U0126 increased FGF21 expression in the absence of FGF21 treatment. Collectively, these data demonstrate that activation of mTORC1 is required for the metabolically beneficial effects of FGF21, specifically glucose uptake, browning, and adiponectin secretion in adipocytes, and to stimulate an autocrine feedback loop through increased FGF21 expression. Consistent with our findings, several studies have found that mTORC1 mediates upregulation of UCP1 and adipocyte browning in response to either cold exposure or b-adrenergic agonists (Liu et al., 2016; Tran et al., 2016) and hyper-activation of mTORC1 in liver and muscle increases circulating FGF21 and weight loss (Cornu et al., 2014; Guridi et al., 2015) .
This raises the question of whether other hormones that activate mTORC1 ( Figure 2B ), most notably insulin, could mimic the effects of FGF21 in adipocytes. Chronic incubation of adipo- cytes with insulin also induced UCP1 mRNA expression, but it did not significantly increase FGF21 mRNA expression ( Figures 3E and 3F ). These data suggest that stimuli aside from FGF21 that activate mTORC1 may also upregulate genes associated with adipocyte browning. We therefore predict that insulin and mTORC1 may upregulate FGF21 and UCP1 to restrain obesity. FGF21 actions may also be enhanced during obesity by high basal mTORC1 activity, and it would be of major interest for future studies to investigate whether mTORC1 mediates FGF21's whole-body effects, such as weight loss and insulin sensitivity in vivo.
FGF21 Signaling Network
Here we performed an unbiased systems analysis of FGF21 signaling. Our data reveal that activation of the FGFR1/bKlotho complex triggers receptor tyrosine auto-phosphorylation, followed by activation of the MAPK pathway and subsequent mTORC1/S6K pathway activity (Figure 4) . The mTORC1/S6K pathway leads to adiponectin secretion, glucose uptake, and UCP1 and FGF21 expression (Figures 3C-3F ). Transcriptional regulation is key for these events; FGF21 upregulates not only UCP1 and FGF21 mRNA but also adiponectin and GLUT1 mRNA (Ge et al., 2011; Lin et al., 2013) . In support of a major effect of FGF21 on transcription, many transcriptional regulators were phosphorylated in response to FGF21 in our phosphoproteomics data (Figure 4) . These include CRTC2, a CREB coactivator that stimulates PGC1a transcription and mitochondrial biogenesis (Wu et al., 2006) ; MORC2a, which is required for differentiation of 3T3-L1 preadipocytes and for expression of genes involved in de novo lipogenesis (Sá nchez-Solana et al., 2014); and NR3C1, a glucocorticoid receptor that regulates the expression of GLUT1 (Sakoda et al., 2000) . These data are valuable resources for identifying key effectors of FGF21 action.
Our findings that mTORC1 is involved in metabolic processes that are implicated in reversing insulin resistance during FGF21 treatment contrast with its proposed role in hyperinsulinemia. By comparing our data with previous phosphoproteomics studies performed in different metabolic tissues and contexts, it is becoming increasingly clear that cells recruit only a specific subset of kinases that integrate and process signals by hormones or stimuli to determine distinct metabolic outputs (Hoffman et al., 2015; Humphrey et al., 2015a; Lundby et al., 2013) . Our data demonstrate the importance of systems-wide analysis of signaling networks in determining how cells process inputs to determine biological outcomes. These data provide insights into the mechanism of FGF21 actions and have implications for treatments designed to improve metabolic disorders, including the use of rapamycin as a health-promoting agent.
EXPERIMENTAL PROCEDURES
For complete details, see the Supplemental Experimental Procedures.
Animals
Mice were fed a standard lab chow diet and group-housed on a 12 hr light/dark cycle with free access to food and water. At 12 weeks of age, mice were injected intraperitoneally with either FGF21 (10 mg/kg) or saline as vehicle control. Mouse experiments were approved by The University of Sydney Animal Ethics Committee.
FGF21 Phosphoproteomics Analysis
3T3-L1 adipocytes underwent SILAC, were serum starved, and were treated with 23 nM FGF21 for 30 s, 2 min, 5 min, and 30 min. Peptides were digested with trypsin (Promega), fractionated by strong cation exchange (SCX), and enriched for phosphopeptides by TiO 2 . Labeled peptides were analyzed by MS, and raw files were processed in MaxQuant.
Cell Assays
Preadipocytes from the SVF were isolated from white subcutaneous fat tissue from 8-to 10-week-old C57BL/6 mice . To assess 2-deoxyglucose (2DOG) uptake, cells were incubated in glucose-free Krebs Ringer buffer (KRP), stimulated with 10 nM insulin for 15 min, exposed to 0.25 mCi/L [ 3 H]-labeled 2-deoxyglucose ([ 3 H]2DOG) (PerkinElmer) in 50 mM unlabeled 2DOG for 5 min, and radioactivity assessed in cell lysates. To assess lipolysis, cells were incubated in KRP supplemented with 3.5% free fatty acid BSA (Sigma-Aldrich). Cells were treated with or without isoproterenol, insulin, or FGF21 for 1 hr as indicated. Aliquots of media were assayed for glycerol content using Sigma glycerol reagent. To assess protein synthesis, adipocytes were incubated in leucine-free DMEM (Sigma-Aldrich) supplemented with [ 3 H]-labeled leucine ([ 3 H]leucine) (5 mCi/mL) (PerkinElmer) and FGF21 or insulin for 1 hr. Protein was precipitated from cell homogenates with 10% trichloroacetic acid (TCA) and radioactivity assessed in TCA-insoluble fractions of cell homogenates. All measurements were normalized to protein concentrations.
Statistical Analysis
The t tests or ANOVAs were performed, as indicated, in GraphPad Prism v.6.01 for Windows. Statistical analysis of proteomics data is described in detail in the Supplemental Experimental Procedures.
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Mouse experiments
12 week old mice were injected intraperitoneally with either FGF21 (10 mg/kg) or saline as vehicle control.
Cell culture
3T3-L1 fibroblasts (Todaro and Green, 1963) phosphopeptides by TiO 2 enrichment as described previously (Humphrey et al., 2013) .
Mass Spectrometry (MS) Bioinformatics analysis
LC-MS/MS analysis was carried out on an LTQ-Orbitrap Velos Pro (Thermo Fisher Scientific) as described previously (Humphrey et al., 2013) . Raw mass spectrometry data were processed using MaxQuant software (Cox and Mann, 2008) was performed using the Andromeda search engine integrated into MaxQuant environment (Cox et al., 2011) against the mouse Uniprot database, (January 2016). Protein, peptide and site FDR thresholds in MaxQuant were each set to a maximum of 1%.
Protein ratios were expressed relative to untreated cells. Only phosphorylation sites quantified in at least one replicate at each time point were retained for statistical analysis.
Subsequently, the top 5% most variable phosphosites at each time point (determined by SD)
were excluded from further analysis. Missing values were imputed using Amelia R package (Honaker et al., 2011) . After missing value imputation, data were normalized by (1) fitting a locally weighted regression curve through the four time points and adjusting the median of the three subsequent time points based of the fitted values; (2) correcting for batch effect using SVA R package (Leek et al.) ; and (3) adjusting the median of the first time point using negative control sites including INSR 1337, INSR 1340, EPHA2 571 and PDGFRA 767.
Significantly regulated phosphopeptides were identified using a moderated t-test implemented in LIMMA package in R (Ritchie et al., 2015) and an adjusted p-value (false discovery rate (FDR) adjustment) cut-off of smaller than 0.01. Consensus amino acid motifs around FGF21-regulated phosphorylation sites at each time point were determined using Seq2Logo (Thomsen and Nielsen, 2012) .
The phosphoproteomics data was analysed for enriched kinases using KSR-LIVE algorithm . Phosphosites changed by greater than 1.5 fold were included in the analysis. A kinase substrate relationship (KSR) database was formed by integrating PhosphositePLUS (retrieved 06/2014), PhosphoELM (release 9.0), PhosphoPOINT (04/2014) and Human Protein Reference Database (release 9). A kinase was predicted to be active if the temporal profile of substrates which are exclusively assigned to that kinase formed a tight cluster. The exclusive substrates in this tight cluster formed the "core substrates" for a kinase. Tight clustering was done as described by Tseng et al. using default parameters. Random data was added to prevent the clustering algorithm splitting apart substrates which follow one time profile. Random data was generated from sampling a uniform distribution in the range of the original data. If a kinase had two or fewer substrates, clustering was not performed. To generate the characteristic temporal profile, exclusive and nonexclusive substrates of a kinase were clustered and the clusters which contained "core substrates" were taken as the characteristic temporal activity of the kinase.
Phosphoproteomics data generated from insulin stimulated adipocytes were processed as described previously (Humphrey et al., 2013) . Kinase perturbation analysis (KinasePA) was used to investigate the coordinated regulation of kinase substrates with respect to 20 mins insulin treatment or 30 mins FGF21 treatment .
Statistical analysis
T-tests or ANOVAs were performed in GraphPad Prism version 6.01 for Windows (GraphPad Software).
Immunoblotting
Cells were washed 3 times with ice-cold PBS and solubilised in 2% SDS in PBS containing protease inhibitors (Roche), and phosphatase inhibitors (1mM sodium pyrophosphate, 2mM sodium orthovanadate, 10mM sodium fluoride). Cells were lysed by sonication for 12 s.
Insoluble material was removed by centrifugation at 21,000×g. Protein concentration was determined by bicinchoninic acid method (Thermo Scientific). 10 µg of protein was resolved by SDS-PAGE and transferred to PVDF membranes. Where indicated, membranes were stained with Sypro Ruby (Thermo Scientific). Then membranes were blocked in 5% skim milk powder in Tris-buffered saline (TBS) buffer for 1 h, followed by an overnight incubation at 4 o C with specific primary antibody solutions. Antibodies specific for S235/S236 pS6, T389 pS6K, S473 pAkt, pT642 pAS160, T246 pPRAS40, Adiponectin were from Cell Signalling Technology; αtubulin from Sigma; 14-3-3β from Santa Cruz. Membranes were incubated with an appropriate secondary for 1 h before signals were detected using ECL (Thermo Scientific or Millipore) on the Chemidoc MP (Bio-Rad). In some cases, IRDye700-or 800-conjugated secondary antibodies were used and then scanned at the 700nm and 800nm channel using the Odyssey IR imager. Densitometry analysis of immunoblots was performed using ImageJ software version 1.47 (Rasband, 1997 (Rasband, -2015 .
2-Deoxyglucose (2DOG) Uptake Assay
3T3-L1 adipocytes in 24-well plates were serum starved in basal-DMEM for 2 h. Cells were then washed 3 times in warm PBS and incubated in Krebs Ringer buffer (KRP) (0.6 mM Na2HPO4, 0.4 mM NaH2PO4, 120 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4 and 12.5 mM Hepes (pH 7.4)) with 0.2 % BSA. µCi/well and 50 µM unlabelled 2DOG were added for 5 min. Glucose uptake was terminated with three rapid washes in ice-cold PBS, after which cells were solubilized in 1% (w/v) Triton X-100 in PBS on a shaker for 1 h and assessed for radioactivity by scintillation counting using a β-scintillation counter. To determine non-specific glucose uptake, cells were treated with 25 µM cytochalasin B 30 min prior to addition of 2DOG. To measure insulin-sensitive glucose uptake, cells were stimulated with 10 nM insulin for 20 min and 2-DOG added in the final 5 min of insulin stimulation. All data was normalised to protein content. Each condition was performed in triplicate.
Lipolysis
3T3-L1 adipocytes in 24-well plates were serum starved in basal-DMEM for 2 h. Cells were washed 3 times in warm PBS and incubated in KRP supplemented with 3.5% free fatty acid BSA (Sigma Aldrich) and 5 mM glucose for 2 h. Cells were treated with or without isoproterenol, insulin or FGF21 for 1 h as indicated. Aliquots of media were taken to assay for glycerol content using Sigma glycerol reagent according to manufacturer's instructions.
The cells were next lysed in 1% (w/v) Triton X-100 in PBS and assessed for protein concentration. Glycerol release was normalised to cellular protein content. Each sample was assayed in duplicate, and the average of the duplicates was considered as one biological replicate. 
qPCR
Total RNA was isolated from cells using Nucleospin RNA columns (Macherey-Nagel). cDNA was prepared from total RNA using the first strand cDNA synthesis kit from Thermo 
